TSTickerStarGet alerts

Apimeds Pharmaceuticals US Reports Q3 2026 Results

Apimeds Pharmaceuticals US reported Q3 2026 revenue of $2.89 million and operating income of $2.0 million, its first full quarter of revenue from technology services following the disposal of its former biopharmaceutical subsidiary on July 14, 2026. Net income was $33.6 million, or $19.13 per basic share and $7.68 per diluted share, which includes a $25.26 million unrealized gain on digital assets. The company disclosed substantial doubt about its ability to continue as a going concern due to a $10.5 million sen...

Share this story

Key takeaways

  • Q3 2026 revenue of $2.89 million, compared with no revenue in Q3 2025, first full quarter of revenue from technology business

  • Q3 2026 operating income of $2.0 million on cost of revenue of $54,300 and G&A expenses of $0.8 million

  • Q3 2026 net income of $33.6 million, including $25.26 million unrealized gain on digital assets

  • Revenue of $2.48 million from software development and deployment services delivered to two enterprise customers

  • Company completed transition by disposing of biopharmaceutical subsidiary on July 14, 2026 (discontinued operations)

  • Total assets of $153.5 million with digital assets representing $142.4 million (93% of total assets)

  • Senior secured convertible note of $10.5 million matures December 8, 2026; substantial doubt about going concern

Key metrics

RevenueQ3 2026
$2.89 millionN/A (no revenue in Q3 2025)
Software development and deployment services revenueQ3 2026
$2.48 million
Operating incomeQ3 2026
$2.0 millionN/A (first operating income quarter)
Net incomeQ3 2026
$33.6 million
Basic EPSQ3 2026
$19.13 per share
Diluted EPSQ3 2026
$7.68 per share
RevenueNine months ended September 30, 2026
$3.2 million
Net lossNine months ended September 30, 2026
$21.6 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Investor relations

Follow APUS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert